|
Disruptions in the Alzheimer’s Disease Market: The Impact of Razadyne's Genericization and the Launch of Biologic Disease-Modifying Drugs
— A Webinar from Decision Resources
Based on our 2008 Physician & Payer Forum report, The Impact of Razadyne's Genericization and the Launch of Biologic Disease-Modifying Drugs on the Alzheimer's Disease Market: Clinician and Payer Receptivity to Novel Agents, Decision Resources is offering an exclusive, in-depth webinar entitled Disruptions in the Alzheimer’s Disease Market: The Impact of Razadyne's Genericization and the Launch of Biologic Disease-Modifying Drugs. Because this webinar will feature major report findings, it is ONLY available to purchasers of this Physician & Payer Forum report.
Please contact us to learn how you can purchase this Physician & Payer Forum report and attend the webinar.
In December 2008, the Alzheimer’s disease (AD) market will undergo major upheaval when Shire/Janssen/Ortho McNeil's Razadyne (galantamine) becomes the first acetylcholinesterase inhibitor to lose market exclusivity in the United States. This webinar, presented by Therapeutic Area Director Andrea Witt, Ph.D., will discuss which brands will be impacted the most by the entry of generic galantamine and which brands will be the best insulated from it.
The webinar will answer the following questions:
- How will the availability of generic galantamine change Primary Care Physicians’ (PCPs) and neurologists’ prescribing patterns and will these changes differ by specialty? How will the availability of generic galantamine impact treatment rates and will it engender earlier treatment and/or longer courses of therapy? Will it encourage wider use of combination therapy?
- Based on plan type, including Medicare PDP and private plans, what are current formulary tier assignments of agents used to treat AD? What factors influence formulary inclusion and how will the availability of generic galantamine impact formulary inclusion of current brands?
- In 2011, the landscape will shift again as the first disease-modifying agents for AD are launched. What factors will influence the uptake of disease-modifying therapies? How will attitudes differ between PCPs and neurologists? What is the magnitude of impact on cognitive decline that would make PCPs and neurologists prescribe a novel agent? Will clinicians prescribe a disease-modifying drug associated with rare but fatal side effects?
- How are clinicians and MCO pharmacy directors aligned and misaligned in their attitudes toward disease-modifying therapies? How will these differences influence the uptake of disease-modifying therapies? What factors influence the tier assignments of emerging disease-modifying agents fulfilling hypothetical profiles? What is the magnitude of impact on cognitive decline that would make pharmacy directors reimburse a novel agent?
Dr. Witt and Analyst Jonathan Searles will conduct a live Q & A session after the presentation.
Disruptions in the Alzheimer’s Disease Market: The Impact of Razadyne's Genericization and the Launch of Biologic Disease-Modifying Drugs
August 26, 2008 at 10 a.m. U.S. Eastern Time, 4 p.m. Central European Time (Paris).
To learn how you can PURCHASE THIS PHYSICIAN & PAYER FORUM REPORT AND ATTEND THIS WEBINAR, please contact:
In North America — Steve Silvestro at 781-296-2626 or ssilvestro@dresources.com
In Europe — Kaj van Langendonck at +32-2-357-06-14 or kvanlangendonck@decisionresources.be
In Japan — Makiko Yoshimoto at +81-3-5401-2615 or makiko@dresources.jp
|
